1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Ketorolac (tromethamine) |
| brand | String | Toradol (IV/IM, US brand discontinued), Sprix (nasal spray), Acular and Acuvail (ophthalmic) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID)]] • [[:Category:Analgesics|Analgesic (opioid-sparing parenteral)]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use''' |
| preparations | String | Tablets 10 mg; injection 15 mg/mL and 30 mg/mL; nasal spray 15.75 mg/spray (Sprix); ophthalmic solution 0.4%, 0.45%, 0.5% |
| fda_max | String | 120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral (continuation only) • IV • IM • intranasal • ophthalmic |
| onset | String | 30 minutes (IM); 30-60 minutes (oral) |
| duration | String | 4-6 hours |
| halflife | String | 5-6 hours'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks. Specifically contraindicated in labor and delivery due to inhibition of uterine contractions'"`UNIQ--ref-00000022-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
